Abstracts Archive - Page 1912 of 2607 - ACR Meeting Abstracts

Abstract Number: 612 • 2015 ACR/ARHP Annual Meeting
Thromboembolic Events Are Not Associated with Anti-Adalimumab Antibodies
Gerd Burmester¹, Cem Gabay², Dilek Arikan³, Anabela Cardoso⁴, Jasmina Kalabic³, Nathan Pfeifer³, Nupun A. Varothai³, Stefan Florentinus⁵ and Josef S. Smolen⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology, Geneva University Hospital, Geneva, Switzerland, ³AbbVie, North Chicago, IL, ⁴Torre Oriente, AbbVie, Lisboa, Portugal, ⁵AbbVie Inc., North Chicago, IL, ⁶Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Treatment of rheumatoid arthritis (RA) with anti-Tumor Necrosis Factor (TNF) such as adalimumab may result in some patients (pts) developing anti-adalimumab antibodies (AAA). Findings…
Abstract Number: 613 • 2015 ACR/ARHP Annual Meeting
Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis
Hiroaki Niiro¹, Hiroshi Tsukamoto², Yojiro Arinobu², Mitsuteru Akahoshi², Hiroki Mitoma², Kensuke Oryoji³, Yasushi Inoue⁴, Takuya Sawabe⁵, Shuji Nagano⁶, Hiroaki Nishizaka⁷, Seiji Yoshizawa⁸, Yoshifumi Tada⁹, Shigeru Yoshizawa¹⁰, Takeshi Otsuka¹¹, Akira Ueda¹², Hitoshi Nakashima¹³, Takahiko Horiuchi¹⁴ and Koichi Akashi², ¹Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³The Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁴Department of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ⁵Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan, ⁶Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁷Kitakyushu Municipal Medical Center, Kitakyushu, Japan, ⁸Hamanomachi Hospital, Fukuoka, Japan, ⁹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ¹⁰Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, ¹¹Munakata Medical Association Hospital, Munakata, Japan, ¹²Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan, ¹³Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ¹⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Despite their profound inhibitory effects on inflammation and bone destruction, it remains unclear whether biological therapies can improve the long-term prognosis of patients with…
Abstract Number: 614 • 2015 ACR/ARHP Annual Meeting
Time to First Signs of Loss of Response in Rheumatoid Arthritis Patients Treated with Anti TNF Agents: Correlations with Serum Drug Level, Immunogenicity and Csdmard Association
Diana Mazilu¹, Daniela Opris^1,2, Evelina Iachim³, Claudia Deaconu⁴, Ioana Saulescu¹, Andreea Borangiu¹, Laura Grosanu¹, Cosmin Constantinescu¹, Andra Balanescu¹, Denisa Predeteanu¹ and Ruxandra Ionescu¹, ¹University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Rheumatology and Internal Medicine, Carol Davila Medicine and Pharmacy University, Sfanta Maria Clinical Hospital, Bucharest, Romania, ³Carol Davila Medicine and Pharmacy University, Bucharest, Romania, ⁴Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania
Background/Purpose: Drug immunogenicity is one of the main mechanisms behind therapeutic failure in rheumatoid arthritis (RA) patients. Our aim was to follow for 2 years…
Abstract Number: 615 • 2015 ACR/ARHP Annual Meeting
Rituximab Non Responders Fail to Down Regulated CD19 on Naive B Cells
Hans-Peter Brezinschek¹, Florentine Fürst-Moazedi¹, Sonja Kielhauser², Martin Stradner³ and Winfried Graninger⁴, ¹Internal Medicine/Division of Rheumatology, Medical University Graz, Graz, Austria, ²Internal Medicine/Division of Rheumatology and Immunology, Medical University Graz, Graz, Austria, ³Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: CD19 is a membrane glycoprotein of the immunoglobulin superfamily and part of the hetero-oligomeric complex comprising the complement receptor type 2, which positively regulates…
Abstract Number: 616 • 2015 ACR/ARHP Annual Meeting
Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD
Tamao Nakashita¹, Akira Dibatake², Kotaro Matsumoto³, Yoto Hamada⁴ and Shinji Motojima⁵, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan, ³Department of Rheumatology and Allergy, Kameda Medical Center, kamogawa, Japan, ⁴Department of Rheumatology and Allergy, Kameda Medical Center, Kamogwa, Japan, ⁵Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of death…
Abstract Number: 617 • 2015 ACR/ARHP Annual Meeting
Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients
Juan P. Vinicki¹, Miguel Arredondo¹, Esther Ramirez², Ana M. Ortiz Garcia³, Santos Castañeda⁴, Alberto Morell¹, Rosario Garcia-Vicuña³ and Jose María Alvaro-Gracia⁴, ¹Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Farmacia, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Down-titration of biological therapy (BT) in rheumatoid arthritis (RA) patients with a good clinical response is frequently applied in daily clinical practice. An important…
Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…
Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Maria de Hair, Nicole IJff, Johannes Jacobs and Jacob van Laar, Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…
Abstract Number: 620 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patients from the Non-Biologic Arms of Inflammatory Arthritis Clinical Trials Identifies Several Predictors of Remission, As Well As, Distinct Responder Subgroups
Brian Tom¹ and Deborah P.M. Symmons², ¹Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: The RA-MAP consortium is a UK flagship industry-academic partnership investigating clinical and biological predictors of disease outcome in patients with rheumatoid arthritis (RA). Methods:…
Abstract Number: 621 • 2015 ACR/ARHP Annual Meeting
Previous Diagnosis of Sjögren’s Syndrome As Rheumatoid Arthritis or Systemic Lupus Erythematosus
Astrid Rasmussen¹, Lida Radfar², Kiely Grundahl³, David M. Lewis⁴, Donald U Stone^5,6, C. Erick Kaufman⁷, Daniel J Wallace⁸, Michael H. Weisman⁹, Swamy Venuturupalli¹⁰, Christopher J Lessard¹¹, Biji Kurien¹², Juan-Manuel Anaya¹³, Michael D. Rohrer¹⁴, Raj Gopalakrishnan¹⁵, Glen D Houston¹⁶, James Chodosh¹⁷, Pamela J Hughes¹⁸, Nelson L. Rhodus¹⁹, John Ice¹, Kimberly Hefner²⁰, Jennifer A. Kelly²¹, Kathy L. Sivils¹ and R. Hal Scofield^1,22,23, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁴College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, ⁶Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁷College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center, West Hollywood, CA, ¹¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁴Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁵Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ¹⁶Heartland Pathology, Oklahoma City, OK, ¹⁷Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹⁸Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, ¹⁹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁰Hefner Eye Care and Optical Center, Oklahoma City, OK, ²¹Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²³US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: The diagnosis of Sjögren′s Syndrome (SS) is often difficult and many patients are symptomatic for years with other diagnoses before confirmation of SS. Overlapping…
Abstract Number: 622 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes
Frederick B Vivino¹, Gary Foulks², S. Lance Forstot³, Peter Donshik⁴, Joseph Forstot⁵, Michael Goldstein⁶, Michael Lemp⁷, J. Daniel Nelson^8,9, Kelly K. Nichols^10,11, Stephen C. Pflugfelder¹², Jason Tanzer¹³, Penny Asbell¹⁴, Deborah S. Jacobs^15,16, Katherine M Hammitt¹⁷ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY, ³Corneal Consultants of Colorado, Littleton, CO, ⁴Department of Ophthalmology, University of Connecticut Health Center, Farmington, CT, ⁵Rheumatology Associates of South Florida, Boca Raton, FL, ⁶New England Eye Center, Tufts Medical Center, Boston, MA, ⁷Department of Ophthalmology, Georgetown University, Washington, DC, ⁸Ophthalmology, HealthPartners Specialty Center, St. Paul, MN, ⁹Dept. of Ophthalmology, University of Minnesota, St. Paul, MN, ¹⁰School of Optometry, The University of Alabama at Birmingham, Birmingham, AL, ¹¹College of Optometry, (formerly) University of Houston, Houston, TX, ¹²Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, TX, ¹³Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental Medicine, Farmington, CT, ¹⁴Dept of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁵Boston Foundation for Sight, Needham, MA, ¹⁶Cornea and External Diseases, Massachusetts Eye and Ear, Boston, MA, ¹⁷Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: Dry eyes can compromise quality of life in Sjogren’s Syndrome (SS) and is often one of the most troublesome symptoms. Clinical practice guidelines were…
Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 624 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Oral Disease Management: Caries Prevention
Frederick B Vivino¹, Domenick Zero², Michael Brennan³, Troy Daniels⁴, Carol Stewart⁵, Athena Papas⁶, Andres Pinto⁷, James Sciubba⁸, Ibtisam Al-Hashimi⁹, Mahvash Navazesh¹⁰, Nelson L. Rhodus¹¹, Mabi Singh¹², Ava Wu¹³, Philip Fox¹⁴, Stephen Cohen¹⁵, Theresa Lawrence Ford¹⁶, Sharon Tracy¹⁷, Julie Frantsve-Hawley¹⁷, Katherine M. Hammitt¹⁴ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Indiana University School of Dentistry, Indianapolis, IN, ³Carolinas Medical Center, Charlotte, NC, ⁴Orofacial Sciences, UCSF School of Medicine & Dentistry, San Francisco, CA, ⁵University of Florida College of Dentistry, Gainesville, FL, ⁶Oral Medicine, Tufts University, Boston, MA, ⁷Case Western Reserve University, Cleveland, OH, ⁸The John Hopkins School of Medicine, Baltimore, MD, ⁹Baylor College of Dentistry, Dallas, TX, ¹⁰University of Southern California, Los Angeles, CA, ¹¹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ¹²Tufts University School of Dental Medicine, Boston, MA, ¹³University of California School of Dentistry, San Francisco, CA, ¹⁴Sjögren's Syndrome Foundation, Bethesda, MD, ¹⁵Dr. Stephen Cohen-Doctor My Eyes, Scottsdale, AZ, ¹⁶North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹⁷American Dental Association, Chicago, IL
Background/Purpose: Salivary dysfunction in Sjögren’s (SS) can lead to serious and costly oral complications including accelerated caries and, in some cases, loss of dentition. Clinical…
Abstract Number: 625 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease
Frederick B Vivino¹, Steven E. Carsons², Ann Parke³, Nancy Carteron⁴, Vidya Sankar⁵, Richard Brasington⁶, Robert Fox⁷, William Ehlers³, Michael Brennan⁸, Robert Hal Scofield⁹, Katherine M Hammitt¹⁰ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, ³University of Connecticut, Farmington, CT, ⁴University of California, San Francisco, CA, ⁵Univeristy of Texas, San Antonio, TX, ⁶Washington University, St Louis, MO, ⁷Rheumatology Clinic, La Jolla, CA, ⁸Carolinas Medical Center, Charlotte, NC, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁰Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: There are currently no FDA approved immunomodulating agents available for treatment of the extraglandular manifestations of Sjogren’s (SS). Clinical practice guidelines were developed for…
Abstract Number: 626 • 2015 ACR/ARHP Annual Meeting
Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Luca Quartuccio¹, Sara Salvin², Laura Corazza¹, Saviana Gandolfo², Martina Fabris³ and Salvatore De Vita⁴, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Rheumatology Clinic, University of Udine, Udine, Italy, ³Clinic of Rheumatology, University of Udine, Udine, Italy, ⁴Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody is preliminary found to be effective in Sjögren’s syndrome (SS) patients with moderate to high systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].